Advertisement
| data science in pharmaceutical industry: The Era of Artificial Intelligence, Machine Learning, and Data Science in the Pharmaceutical Industry Stephanie K. Ashenden, 2021-04-23 The Era of Artificial Intelligence, Machine Learning and Data Science in the Pharmaceutical Industry examines the drug discovery process, assessing how new technologies have improved effectiveness. Artificial intelligence and machine learning are considered the future for a wide range of disciplines and industries, including the pharmaceutical industry. In an environment where producing a single approved drug costs millions and takes many years of rigorous testing prior to its approval, reducing costs and time is of high interest. This book follows the journey that a drug company takes when producing a therapeutic, from the very beginning to ultimately benefitting a patient's life. This comprehensive resource will be useful to those working in the pharmaceutical industry, but will also be of interest to anyone doing research in chemical biology, computational chemistry, medicinal chemistry and bioinformatics. - Demonstrates how the prediction of toxic effects is performed, how to reduce costs in testing compounds, and its use in animal research - Written by the industrial teams who are conducting the work, showcasing how the technology has improved and where it should be further improved - Targets materials for a better understanding of techniques from different disciplines, thus creating a complete guide |
| data science in pharmaceutical industry: Trends and Innovations in Information Systems and Technologies Álvaro Rocha, Hojjat Adeli, Luís Paulo Reis, Sandra Costanzo, Irena Orovic, Fernando Moreira, 2020-05-18 This book gathers selected papers presented at the 2020 World Conference on Information Systems and Technologies (WorldCIST’20), held in Budva, Montenegro, from April 7 to 10, 2020. WorldCIST provides a global forum for researchers and practitioners to present and discuss recent results and innovations, current trends, professional experiences with and challenges regarding various aspects of modern information systems and technologies. The main topics covered are A) Information and Knowledge Management; B) Organizational Models and Information Systems; C) Software and Systems Modeling; D) Software Systems, Architectures, Applications and Tools; E) Multimedia Systems and Applications; F) Computer Networks, Mobility and Pervasive Systems; G) Intelligent and Decision Support Systems; H) Big Data Analytics and Applications; I) Human–Computer Interaction; J) Ethics, Computers & Security; K) Health Informatics; L) Information Technologies in Education; M) Information Technologies in Radiocommunications; and N) Technologies for Biomedical Applications. |
| data science in pharmaceutical industry: Multivariate Analysis in the Pharmaceutical Industry Ana Patricia Ferreira, Jose C. Menezes, Mike Tobyn, 2018-04-24 Multivariate Analysis in the Pharmaceutical Industry provides industry practitioners with guidance on multivariate data methods and their applications over the lifecycle of a pharmaceutical product, from process development, to routine manufacturing, focusing on the challenges specific to each step. It includes an overview of regulatory guidance specific to the use of these methods, along with perspectives on the applications of these methods that allow for testing, monitoring and controlling products and processes. The book seeks to put multivariate analysis into a pharmaceutical context for the benefit of pharmaceutical practitioners, potential practitioners, managers and regulators. Users will find a resources that addresses an unmet need on how pharmaceutical industry professionals can extract value from data that is routinely collected on products and processes, especially as these techniques become more widely used, and ultimately, expected by regulators. - Targets pharmaceutical industry practitioners and regulatory staff by addressing industry specific challenges - Includes case studies from different pharmaceutical companies and across product lifecycle of to introduce readers to the breadth of applications - Contains information on the current regulatory framework which will shape how multivariate analysis (MVA) is used in years to come |
| data science in pharmaceutical industry: Lattice Deepayan Sarkar, 2008-02-15 Written by the author of the lattice system, this book describes lattice in considerable depth, beginning with the essentials and systematically delving into specific low levels details as necessary. No prior experience with lattice is required to read the book, although basic familiarity with R is assumed. The book contains close to 150 figures produced with lattice. Many of the examples emphasize principles of good graphical design; almost all use real data sets that are publicly available in various R packages. All code and figures in the book are also available online, along with supplementary material covering more advanced topics. |
| data science in pharmaceutical industry: Bad Pharma Ben Goldacre, 2014-04 Originally published in 2012, revised edition published in 2013, by Fourth Estate, Great Britain; Published in the United States in 2012, revised edition also, by Faber and Faber, Inc. |
| data science in pharmaceutical industry: GAMP 5 Sion Wyn, 2008 GAMP 5 provides pragmatic and practical industry guidance to achieve compliant computerized systems fit for intended use in an efficient and effective manner. This technical document describes a flexible risk-based approach to compliant GxP regulated computerized systems, based on scalable specification and verification. It points to the future of computer systems compliance by centering on principles behind major industry developments such as PQLI; ICH Q8, Q9, Q10; and ASTM E2500. This revolutionary Guide addresses the entire lifecycle of an automated system and its applicability to a wide range of information systems, lab equipment, integrated manufacturing systems, and IT infrastructures. It contains new information on outsourcing, electronic batch recording, end user applications (such as spreadsheets and small database applications), and patch management. |
| data science in pharmaceutical industry: Artificial Intelligence in Healthcare Adam Bohr, Kaveh Memarzadeh, 2020-06-21 Artificial Intelligence (AI) in Healthcare is more than a comprehensive introduction to artificial intelligence as a tool in the generation and analysis of healthcare data. The book is split into two sections where the first section describes the current healthcare challenges and the rise of AI in this arena. The ten following chapters are written by specialists in each area, covering the whole healthcare ecosystem. First, the AI applications in drug design and drug development are presented followed by its applications in the field of cancer diagnostics, treatment and medical imaging. Subsequently, the application of AI in medical devices and surgery are covered as well as remote patient monitoring. Finally, the book dives into the topics of security, privacy, information sharing, health insurances and legal aspects of AI in healthcare. - Highlights different data techniques in healthcare data analysis, including machine learning and data mining - Illustrates different applications and challenges across the design, implementation and management of intelligent systems and healthcare data networks - Includes applications and case studies across all areas of AI in healthcare data |
| data science in pharmaceutical industry: Emergence of Pharmaceutical Industry Growth with Industrial IoT Approach Valentina Emilia Balas, Vijender Kumar Solanki, Raghvendra Kumar, 2019-09-24 Emergence of Pharmaceutical Industry Growth with Industrial IoT Approach uses an innovative approach to explore how the Internet of Things (IoT) and big data can improve approaches, create efficiencies and make discoveries. Rapid growth of the IoT has encouraged many companies in the manufacturing sector to make use of this technology to unlock its potential. Pharmaceutical manufacturing companies are no exception to this, as IoT has the potential to revolutionize aspects of the pharmaceutical manufacturing process, from drug discovery to manufacturing. Using clear, concise language and real world case studies, this book discusses systems level from both a human-factors point-of-view and the perspective of networking, databases, privacy and anti-spoofing. The wide variety of topics presented offers readers multiple perspectives on a how to integrate the Internet of Things into pharmaceutical manufacturing. - Covers efficiency improvements of pharmaceutical manufacturing through IoT/Big Data approaches - Explores cutting-edge technologies through sensor enabled environment in the pharmaceutical industry - Discusses the systems level from both a human-factors point-of-view and the perspective of networking, databases, privacy and anti-spoofing |
| data science in pharmaceutical industry: Sharing Clinical Trial Data Institute of Medicine, Board on Health Sciences Policy, Committee on Strategies for Responsible Sharing of Clinical Trial Data, 2015-04-20 Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge and benefits to be gained from the efforts of clinical trial participants and investigators. At the same time, sharing clinical trial data presents risks, burdens, and challenges. These include the need to protect the privacy and honor the consent of clinical trial participants; safeguard the legitimate economic interests of sponsors; and guard against invalid secondary analyses, which could undermine trust in clinical trials or otherwise harm public health. Sharing Clinical Trial Data presents activities and strategies for the responsible sharing of clinical trial data. With the goal of increasing scientific knowledge to lead to better therapies for patients, this book identifies guiding principles and makes recommendations to maximize the benefits and minimize risks. This report offers guidance on the types of clinical trial data available at different points in the process, the points in the process at which each type of data should be shared, methods for sharing data, what groups should have access to data, and future knowledge and infrastructure needs. Responsible sharing of clinical trial data will allow other investigators to replicate published findings and carry out additional analyses, strengthen the evidence base for regulatory and clinical decisions, and increase the scientific knowledge gained from investments by the funders of clinical trials. The recommendations of Sharing Clinical Trial Data will be useful both now and well into the future as improved sharing of data leads to a stronger evidence base for treatment. This book will be of interest to stakeholders across the spectrum of research-from funders, to researchers, to journals, to physicians, and ultimately, to patients. |
| data science in pharmaceutical industry: Research and Development in the Pharmaceutical Industry (A CBO Study) Congressional Budget Office, 2013-06-09 Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation... |
| data science in pharmaceutical industry: Encyclopedia of Data Science and Machine Learning Wang, John, 2023-01-20 Big data and machine learning are driving the Fourth Industrial Revolution. With the age of big data upon us, we risk drowning in a flood of digital data. Big data has now become a critical part of both the business world and daily life, as the synthesis and synergy of machine learning and big data has enormous potential. Big data and machine learning are projected to not only maximize citizen wealth, but also promote societal health. As big data continues to evolve and the demand for professionals in the field increases, access to the most current information about the concepts, issues, trends, and technologies in this interdisciplinary area is needed. The Encyclopedia of Data Science and Machine Learning examines current, state-of-the-art research in the areas of data science, machine learning, data mining, and more. It provides an international forum for experts within these fields to advance the knowledge and practice in all facets of big data and machine learning, emphasizing emerging theories, principals, models, processes, and applications to inspire and circulate innovative findings into research, business, and communities. Covering topics such as benefit management, recommendation system analysis, and global software development, this expansive reference provides a dynamic resource for data scientists, data analysts, computer scientists, technical managers, corporate executives, students and educators of higher education, government officials, researchers, and academicians. |
| data science in pharmaceutical industry: Data Analytics in Biomedical Engineering and Healthcare Kun Chang Lee, Sanjiban Sekhar Roy, Pijush Samui, Vijay Kumar, 2020-10-18 Data Analytics in Biomedical Engineering and Healthcare explores key applications using data analytics, machine learning, and deep learning in health sciences and biomedical data. The book is useful for those working with big data analytics in biomedical research, medical industries, and medical research scientists. The book covers health analytics, data science, and machine and deep learning applications for biomedical data, covering areas such as predictive health analysis, electronic health records, medical image analysis, computational drug discovery, and genome structure prediction using predictive modeling. Case studies demonstrate big data applications in healthcare using the MapReduce and Hadoop frameworks. - Examines the development and application of data analytics applications in biomedical data - Presents innovative classification and regression models for predicting various diseases - Discusses genome structure prediction using predictive modeling - Shows readers how to develop clinical decision support systems - Shows researchers and specialists how to use hybrid learning for better medical diagnosis, including case studies of healthcare applications using the MapReduce and Hadoop frameworks |
| data science in pharmaceutical industry: Applications of Machine Learning Prashant Johri, Jitendra Kumar Verma, Sudip Paul, 2020-05-04 This book covers applications of machine learning in artificial intelligence. The specific topics covered include human language, heterogeneous and streaming data, unmanned systems, neural information processing, marketing and the social sciences, bioinformatics and robotics, etc. It also provides a broad range of techniques that can be successfully applied and adopted in different areas. Accordingly, the book offers an interesting and insightful read for scholars in the areas of computer vision, speech recognition, healthcare, business, marketing, and bioinformatics. |
| data science in pharmaceutical industry: Pharmaceutical Data Mining Konstantin V. Balakin, 2009-11-19 Leading experts illustrate how sophisticated computational data mining techniques can impact contemporary drug discovery and development In the era of post-genomic drug development, extracting and applying knowledge from chemical, biological, and clinical data is one of the greatest challenges facing the pharmaceutical industry. Pharmaceutical Data Mining brings together contributions from leading academic and industrial scientists, who address both the implementation of new data mining technologies and application issues in the industry. This accessible, comprehensive collection discusses important theoretical and practical aspects of pharmaceutical data mining, focusing on diverse approaches for drug discovery—including chemogenomics, toxicogenomics, and individual drug response prediction. The five main sections of this volume cover: A general overview of the discipline, from its foundations to contemporary industrial applications Chemoinformatics-based applications Bioinformatics-based applications Data mining methods in clinical development Data mining algorithms, technologies, and software tools, with emphasis on advanced algorithms and software that are currently used in the industry or represent promising approaches In one concentrated reference, Pharmaceutical Data Mining reveals the role and possibilities of these sophisticated techniques in contemporary drug discovery and development. It is ideal for graduate-level courses covering pharmaceutical science, computational chemistry, and bioinformatics. In addition, it provides insight to pharmaceutical scientists, principal investigators, principal scientists, research directors, and all scientists working in the field of drug discovery and development and associated industries. |
| data science in pharmaceutical industry: Careers with the Pharmaceutical Industry Peter D. Stonier, 2003-05-07 In recent years, many factors have combined to change the operating environment of the international pharmaceutical industry leading to greater specialisation and sophistication. This new edition will give an update of the different opportunities in drug discovery and development and the scientific, medical or other specialist training needed to accomplish them. The scope of this edition has been broadened to encompass all major roles, including marketing and sales. |
| data science in pharmaceutical industry: Artificial Intelligence in Drug Discovery Nathan Brown, 2020-11-04 Following significant advances in deep learning and related areas interest in artificial intelligence (AI) has rapidly grown. In particular, the application of AI in drug discovery provides an opportunity to tackle challenges that previously have been difficult to solve, such as predicting properties, designing molecules and optimising synthetic routes. Artificial Intelligence in Drug Discovery aims to introduce the reader to AI and machine learning tools and techniques, and to outline specific challenges including designing new molecular structures, synthesis planning and simulation. Providing a wealth of information from leading experts in the field this book is ideal for students, postgraduates and established researchers in both industry and academia. |
| data science in pharmaceutical industry: Applied Statistics in the Pharmaceutical Industry Steven P. Millard, Andreas Krause, 2013-11-09 Providing a general guide to statistical methods used in the pharmaceutical industry, and illustrating how to use S-PLUS to implement these methods, the book explains why S-PLUS is a useful software package and discusses the results and implications of each particular application. It is targeted at graduates in biostatistics, statisticians involved in the industry as research scientists, regulators, academics, and/or consultants who want to know more about how to use S-PLUS and learn about other sub-fields within the industry, as well as statisticians in other fields who want to know more about statistical applications in the pharmaceutical industry. |
| data science in pharmaceutical industry: Medical Science and Medical Industry J. Liebenau, 1987-06-18 |
| data science in pharmaceutical industry: Data Science, AI, and Machine Learning in Drug Development Harry Yang, 2022-10-04 The confluence of big data, artificial intelligence (AI), and machine learning (ML) has led to a paradigm shift in how innovative medicines are developed and healthcare delivered. To fully capitalize on these technological advances, it is essential to systematically harness data from diverse sources and leverage digital technologies and advanced analytics to enable data-driven decisions. Data science stands at a unique moment of opportunity to lead such a transformative change. Intended to be a single source of information, Data Science, AI, and Machine Learning in Drug Research and Development covers a wide range of topics on the changing landscape of drug R & D, emerging applications of big data, AI and ML in drug development, and the build of robust data science organizations to drive biopharmaceutical digital transformations. Features Provides a comprehensive review of challenges and opportunities as related to the applications of big data, AI, and ML in the entire spectrum of drug R & D Discusses regulatory developments in leveraging big data and advanced analytics in drug review and approval Offers a balanced approach to data science organization build Presents real-world examples of AI-powered solutions to a host of issues in the lifecycle of drug development Affords sufficient context for each problem and provides a detailed description of solutions suitable for practitioners with limited data science expertise |
| data science in pharmaceutical industry: Improving and Accelerating Therapeutic Development for Nervous System Disorders Institute of Medicine, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, 2014-02-06 Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials. |
| data science in pharmaceutical industry: Solid State Development and Processing of Pharmaceutical Molecules Michael Gruss, 2021-11-15 Solid State Development and Processing of Pharmaceutical Molecules A guide to the lastest industry principles for optimizing the production of solid state active pharmaceutical ingredients Solid State Development and Processing of Pharmaceutical Molecules is an authoritative guide that covers the entire pharmaceutical value chain. The authors—noted experts on the topic—examine the importance of the solid state form of chemical and biological drugs and review the development, production, quality control, formulation, and stability of medicines. The book explores the most recent trends in the digitization and automation of the pharmaceutical production processes that reflect the need for consistent high quality. It also includes information on relevant regulatory and intellectual property considerations. This resource is aimed at professionals in the pharmaceutical industry and offers an in-depth examination of the commercially relevant issues facing developers, producers and distributors of drug substances. This important book: Provides a guide for the effective development of solid drug forms Compares different characterization methods for solid state APIs Offers a resource for understanding efficient production methods for solid state forms of chemical and biological drugs Includes information on automation, process control, and machine learning as an integral part of the development and production workflows Covers in detail the regulatory and quality control aspects of drug development Written for medicinal chemists, pharmaceutical industry professionals, pharma engineers, solid state chemists, chemical engineers, Solid State Development and Processing of Pharmaceutical Molecules reviews information on the solid state of active pharmaceutical ingredients for their efficient development and production. |
| data science in pharmaceutical industry: Open Source Software in Life Science Research Lee Harland, Mark Forster, 2012-10-31 The free/open source approach has grown from a minor activity to become a significant producer of robust, task-orientated software for a wide variety of situations and applications. To life science informatics groups, these systems present an appealing proposition - high quality software at a very attractive price. Open source software in life science research considers how industry and applied research groups have embraced these resources, discussing practical implementations that address real-world business problems.The book is divided into four parts. Part one looks at laboratory data management and chemical informatics, covering software such as Bioclipse, OpenTox, ImageJ and KNIME. In part two, the focus turns to genomics and bioinformatics tools, with chapters examining GenomicsTools and EBI Atlas software, as well as the practicalities of setting up an 'omics' platform and managing large volumes of data. Chapters in part three examine information and knowledge management, covering a range of topics including software for web-based collaboration, open source search and visualisation technologies for scientific business applications, and specific software such as DesignTracker and Utopia Documents. Part four looks at semantic technologies such as Semantic MediaWiki, TripleMap and Chem2Bio2RDF, before part five examines clinical analytics, and validation and regulatory compliance of free/open source software. Finally, the book concludes by looking at future perspectives and the economics and free/open source software in industry. - Discusses a broad range of applications from a variety of sectors - Provides a unique perspective on work normally performed behind closed doors - Highlights the criteria used to compare and assess different approaches to solving problems |
| data science in pharmaceutical industry: Essential Statistics for the Pharmaceutical Sciences Philip Rowe, 2015-07-20 Essential Statistics for the Pharmaceutical Sciences is targeted at all those involved in research in pharmacology, pharmacy or other areas of pharmaceutical science; everybody from undergraduate project students to experienced researchers should find the material they need. This book will guide all those who are not specialist statisticians in using sound statistical principles throughout the whole journey of a research project - designing the work, selecting appropriate statistical methodology and correctly interpreting the results. It deliberately avoids detailed calculation methodology. Its key features are friendliness and clarity. All methods are illustrated with realistic examples from within pharmaceutical science. This edition now includes expanded coverage of some of the topics included in the first edition and adds some new topics relevant to pharmaceutical research. a clear, accessible introduction to the key statistical techniques used within the pharmaceutical sciences all examples set in relevant pharmaceutical contexts. key points emphasised in summary boxes and warnings of potential abuses in ‘pirate boxes’. supplementary material - full data sets and detailed instructions for carrying out analyses using packages such as SPSS or Minitab – provided at: https://www.wiley.com/go/rowe/statspharmascience2e An invaluable introduction to statistics for any science student and an essential text for all those involved in pharmaceutical research at whatever level. |
| data science in pharmaceutical industry: Statistics In the Pharmaceutical Industry, 3rd Edition C. Ralph Buncher, Jia-Yeong Tsay, 2005-09-28 The growth of the pharmaceutical industry over the past decade is astounding, but the impact of this growth on statistics is somewhat confusing. While software has made analysis easier and more efficient, regulatory bodies now demand deeper and more complex analyses, and pharmacogenetic/genomic studies serve up an entirely new set of challenges. For more than two decades, Statistics in the Pharmaceutical Industry has been the definitive guide to sorting through the challenges in the industry, and this Third Edition continues that tradition. Updated and expanded to reflect the most recent trends and developments in the field, Statistics in the Pharmaceutical Industry, Third Edition presents chapters written by experts from both regulatory agencies and pharmaceutical companies who discuss everything from experimental design to post-marketing studies. This approach sheds light on what regulators consider acceptable methodologies and what methods have proven successful for industrial statisticians. Both new and revised chapters reflect the increasingly global nature of the industry as represented by authors from Japan and Europe, the increasing trend toward non-inferiority/equivalence testing, adaptive design in clinical trials, global harmonization of regulatory standards, and multiple comparison studies. The book also examines the latest considerations in anti-cancer studies. Statistics in the Pharmaceutical Industry, Third Edition demystifies the approval process by combining regulatory and industrial points of view, making it a must-read for anyone performing statistical analysis at any point in the drug approval process. |
| data science in pharmaceutical industry: Pharmaceutical Sales Data 101 Kosta Tzavaras, 2003 |
| data science in pharmaceutical industry: Business Intelligence Demystified Anoop Kumar V K, 2021-09-25 Clear your doubts about Business Intelligence and start your new journey KEY FEATURES ● Includes successful methods and innovative ideas to achieve success with BI. ● Vendor-neutral, unbiased, and based on experience. ● Highlights practical challenges in BI journeys. ● Covers financial aspects along with technical aspects. ● Showcases multiple BI organization models and the structure of BI teams. DESCRIPTION The book demystifies misconceptions and misinformation about BI. It provides clarity to almost everything related to BI in a simplified and unbiased way. It covers topics right from the definition of BI, terms used in the BI definition, coinage of BI, details of the different main uses of BI, processes that support the main uses, side benefits, and the level of importance of BI, various types of BI based on various parameters, main phases in the BI journey and the challenges faced in each of the phases in the BI journey. It clarifies myths about self-service BI and real-time BI. The book covers the structure of a typical internal BI team, BI organizational models, and the main roles in BI. It also clarifies the doubts around roles in BI. It explores the different components that add to the cost of BI and explains how to calculate the total cost of the ownership of BI and ROI for BI. It covers several ideas, including unconventional ideas to achieve BI success and also learn about IBI. It explains the different types of BI architectures, commonly used technologies, tools, and concepts in BI and provides clarity about the boundary of BI w.r.t technologies, tools, and concepts. The book helps you lay a very strong foundation and provides the right perspective about BI. It enables you to start or restart your journey with BI. WHAT YOU WILL LEARN ● Builds a strong conceptual foundation in BI. ● Gives the right perspective and clarity on BI uses, challenges, and architectures. ● Enables you to make the right decisions on the BI structure, organization model, and budget. ● Explains which type of BI solution is required for your business. ● Applies successful BI ideas. WHO THIS BOOK IS FOR This book is a must-read for business managers, BI aspirants, CxOs, and all those who want to drive the business value with data-driven insights. TABLE OF CONTENTS 1. What is Business Intelligence? 2. Why do Businesses need BI? 3. Types of Business Intelligence 4. Challenges in Business Intelligence 5. Roles in Business Intelligence 6. Financials of Business Intelligence 7. Ideas for Success with BI 8. Introduction to IBI 9. BI Architectures 10. Demystify Tech, Tools, and Concepts in BI |
| data science in pharmaceutical industry: Artificial Intelligence for Drug Development, Precision Medicine, and Healthcare Mark Chang, 2020-05-12 Artificial Intelligence for Drug Development, Precision Medicine, and Healthcare covers exciting developments at the intersection of computer science and statistics. While much of machine-learning is statistics-based, achievements in deep learning for image and language processing rely on computer science’s use of big data. Aimed at those with a statistical background who want to use their strengths in pursuing AI research, the book: · Covers broad AI topics in drug development, precision medicine, and healthcare. · Elaborates on supervised, unsupervised, reinforcement, and evolutionary learning methods. · Introduces the similarity principle and related AI methods for both big and small data problems. · Offers a balance of statistical and algorithm-based approaches to AI. · Provides examples and real-world applications with hands-on R code. · Suggests the path forward for AI in medicine and artificial general intelligence. As well as covering the history of AI and the innovative ideas, methodologies and software implementation of the field, the book offers a comprehensive review of AI applications in medical sciences. In addition, readers will benefit from hands on exercises, with included R code. |
| data science in pharmaceutical industry: Data Science in the Medical Field Seifedine Kadry, Shubham Mahajan, 2024-09-30 ata science has the potential to influence and improve fundamental services such as the healthcare sector. This book recognizes this fact by analyzing the potential uses of data science in healthcare. Every human body produces 2 TB of data each day. This information covers brain activity, stress level, heart rate, blood sugar level, and many other things. More sophisticated technology, such as data science, allows clinicians and researchers to handle such a massive volume of data to track the health of patients. The book focuses on the potential and the tools of data science to identify the signs of illness at an extremely early stage. • Shows how improving automated analytical techniques can be used to generate new information from data for healthcare applications• Combines a number of related fields, with a particular emphasis on machine learning, big data analytics, statistics, pattern recognition, computer vision, and semantic web technologies• Provides information on the cutting-edge data science tools required to accelerate innovation for healthcare organizations and patients by reading this book |
| data science in pharmaceutical industry: Data Science and Medical Informatics in Healthcare Technologies Nguyen Thi Dieu Linh, Zhongyu (Joan) Lu, 2021-06-19 This book highlights a timely and accurate insight at the endeavour of the bioinformatics and genomics clinicians from industry and academia to address the societal needs. The contents of the book unearth the lacuna between the medication and treatment in the current preventive medicinal and pharmaceutical system. It contains chapters prepared by experts in life sciences along with data scientists for examining the circumstances of health care system for the next decade. It also highlights the automated processes for analyzing data in clinical trial research, specifically for drug development. Additionally, the data science solutions provided in this book help pharmaceutical companies to improve on what had historically been manual, costly and laborious process for cross-referencing research in clinical trials on drug development, while laying the groundwork for use with a full range of other drugs for the conditions ranging from tuberculosis, to diabetes, to heart attacks and many others. |
| data science in pharmaceutical industry: Approaching (Almost) Any Machine Learning Problem Abhishek Thakur, 2020-07-04 This is not a traditional book. The book has a lot of code. If you don't like the code first approach do not buy this book. Making code available on Github is not an option. This book is for people who have some theoretical knowledge of machine learning and deep learning and want to dive into applied machine learning. The book doesn't explain the algorithms but is more oriented towards how and what should you use to solve machine learning and deep learning problems. The book is not for you if you are looking for pure basics. The book is for you if you are looking for guidance on approaching machine learning problems. The book is best enjoyed with a cup of coffee and a laptop/workstation where you can code along. Table of contents: - Setting up your working environment - Supervised vs unsupervised learning - Cross-validation - Evaluation metrics - Arranging machine learning projects - Approaching categorical variables - Feature engineering - Feature selection - Hyperparameter optimization - Approaching image classification & segmentation - Approaching text classification/regression - Approaching ensembling and stacking - Approaching reproducible code & model serving There are no sub-headings. Important terms are written in bold. I will be answering all your queries related to the book and will be making YouTube tutorials to cover what has not been discussed in the book. To ask questions/doubts, visit this link: https://bit.ly/aamlquestions And Subscribe to my youtube channel: https://bit.ly/abhitubesub |
| data science in pharmaceutical industry: Science, Politics And The Pharmaceutical Industry John Abraham, 0 John Abraham University of Reading.,, 2023-05-31 Drug disasters from Thalidomide to Opren, and other less dramatic cases of drug injury, raise questions about whether the testing and control of medicines provides satisfactory protection for the public. In this revealing study, John Abrahan develops a theoretically challenging realist approach, in order to probe deeply into the work of scientists in the pharmaceutical industry and governmental drug regulatory authorities on both sides of the Atlantic. Through the examination of contemporary controversial case studies, he exposes how the commercial interest of drug manufacturers are consistently given the benefit of the scientific doubts about medicine safety and effectiveness, over and above the best interests of patients.; A highly original combination of philosophical rigour, historical sensitivity and empirical depth enables the black box of industrial and government science to be opened up to critical scrutiny much more than in previous social scientific study. All major aspects of drug testing and regulation are considered, including pre- clinical animal tests, clinical trials and postmarketing surveillance of adverse drug reactions. The author argues that drug regulators are too dependent on pharmaceutical industry resources and expertise, and too divorced from public accountability. The problem of corporate bias is particularly severe in the UK, where regulatory decisions about medicine safety are shrouded in greater secrecy than in the US.; Since the purpose of drug regulation should be to maximize the safety and effectiveness of medicines for patients, the public needs and deserves policies to counteract corporate bias in drug testing and evaluation. John Abraham's realist analysis provides a robust basis for policy interventions at the institutional and legislative levels. He proposes that corporate bias could be reduced by more extensive freedom of information, greater autonomy of government scientists from pharmaceutical industry, the development of independent drug testing by the regulatory authority, increased patient representation on regulatory committees, and more frequent and thorough oversight of regulatory performance by the legislature. This book should be of interest to anyone who cares about how medicines should be controlled in modern society. It should prove particularly rewarding for students and researchers in the sociology of science and technology, science and medicines policy, medical sociologists, the medical and pharmaceutical professions, and consumer organizations. |
| data science in pharmaceutical industry: Real-World Evidence in Drug Development and Evaluation Harry Yang, Binbing Yu, 2021-01-11 Real-world evidence (RWE) has been at the forefront of pharmaceutical innovations. It plays an important role in transforming drug development from a process aimed at meeting regulatory expectations to an operating model that leverages data from disparate sources to aid business, regulatory, and healthcare decision making. Despite its many benefits, there is no single book systematically covering the latest development in the field. Written specifically for pharmaceutical practitioners, Real-World Evidence in Drug Development and Evaluation, presents a wide range of RWE applications throughout the lifecycle of drug product development. With contributions from experienced researchers in the pharmaceutical industry, the book discusses at length RWE opportunities, challenges, and solutions. Features Provides the first book and a single source of information on RWE in drug development Covers a broad array of topics on outcomes- and value-based RWE assessments Demonstrates proper Bayesian application and causal inference for real-world data (RWD) Presents real-world use cases to illustrate the use of advanced analytics and statistical methods to generate insights Offers a balanced discussion of practical RWE issues at hand and technical solutions suitable for practitioners with limited data science expertise |
| data science in pharmaceutical industry: Statistical Methodology in the Pharmaceutical Sciences D. A. Berry, 2016-04-19 A state-of-the-art handbook of statistical analysis for use in the pharmaceutical industry. Areas covered in this reference/text include: bioavailability, repeated-measures designs, dose-response, population models, multicenter trials, handling dropouts, survival analysis, robust data analysis, cate |
| data science in pharmaceutical industry: Multiple Testing Problems in Pharmaceutical Statistics Alex Dmitrienko, Ajit C. Tamhane, Frank Bretz, 2009-12-08 Useful Statistical Approaches for Addressing Multiplicity IssuesIncludes practical examples from recent trials Bringing together leading statisticians, scientists, and clinicians from the pharmaceutical industry, academia, and regulatory agencies, Multiple Testing Problems in Pharmaceutical Statistics explores the rapidly growing area of multiple c |
| data science in pharmaceutical industry: Fundamentals of Clinical Data Science Pieter Kubben, Michel Dumontier, Andre Dekker, 2018-12-21 This open access book comprehensively covers the fundamentals of clinical data science, focusing on data collection, modelling and clinical applications. Topics covered in the first section on data collection include: data sources, data at scale (big data), data stewardship (FAIR data) and related privacy concerns. Aspects of predictive modelling using techniques such as classification, regression or clustering, and prediction model validation will be covered in the second section. The third section covers aspects of (mobile) clinical decision support systems, operational excellence and value-based healthcare. Fundamentals of Clinical Data Science is an essential resource for healthcare professionals and IT consultants intending to develop and refine their skills in personalized medicine, using solutions based on large datasets from electronic health records or telemonitoring programmes. The book’s promise is “no math, no code”and will explain the topics in a style that is optimized for a healthcare audience. |
| data science in pharmaceutical industry: From Science 2.0 to Pharma 3.0 Hervé Basset, David Stuart, Denise Silber, 2012-09-10 Science 2.0 uses the resources of Web 2.0 to communicate between scientists, and with the general public. Web 3.0, in turn, has brought disruptive technologies such as semantic search, cloud computing and mobile applications into play. The term Pharma 3.0 anticipates the future relationship between drug makers and doctors with their patients in light of such technology. From Science 2.0 to Pharma 3.0 examines these developments, discussing the best and worst of Web 2.0 in science communication and health. Successes such as the Open Access phenomena and also less successful networks are covered. This title is divided into three parts. The first part considers the Web 2.0 revolution, and the promise of its impact on science communication and the state of Science 2.0. The second part looks at impact on Pharma and Health, including attempts to utilise digital in Pharma. The last part looks at the promising disruptive technologies of Web 3.0, including semantic search in biomedicine and enterprise platforms. The book concludes by looking forward to developments of '3.0' in Pharma and STM publishing. - Gives a global overview of success and failure in Science 2.0 - Presents useful stories and lessons learned - Gives a clear view of how semantic search is present in science platforms and its potential in STM publishing |
| data science in pharmaceutical industry: Strengthening a Workforce for Innovative Regulatory Science in Therapeutics Development Institute of Medicine, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, 2012-04-04 The development and application of regulatory science - which FDA has defined as the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products - calls for a well-trained, scientifically engaged, and motivated workforce. FDA faces challenges in retaining regulatory scientists and providing them with opportunities for professional development. In the private sector, advancement of innovative regulatory science in drug development has not always been clearly defined, well coordinated, or connected to the needs of the agency. As a follow-up to a 2010 workshop, the IOM held a workshop on September 20-21, 2011, to provide a format for establishing a specific agenda to implement the vision and principles relating to a regulatory science workforce and disciplinary infrastructure as discussed in the 2010 workshop. |
| data science in pharmaceutical industry: An Industrial IoT Approach for Pharmaceutical Industry Growth Valentina Emilia Balas, Vijender Kumar Solanki, Raghvendra Kumar, 2020-05-15 An Industrial IoT Approach for Pharmaceutical Industry Growth, Volume Two uses an innovative approach to explore how the Internet of Things (IoT) and big data can improve approaches and make discoveries. Rapid growth of the IoT has encouraged many companies in the manufacturing sector to make use of this technology to unlock its potential. Using clear language and real-world case studies, this book discusses systems level from both a human-factors point-of-view and the perspective of networking, databases, privacy and anti-spoofing. The wide variety in topics presented offers multiple perspectives on how to integrate the Internet of Things into pharmaceutical manufacturing.This book represents a useful resource for researchers in pharmaceutical sciences, information and communication technologies, and those who specialize in healthcare and pharmacovigilance. |
| data science in pharmaceutical industry: Storytelling with Data Cole Nussbaumer Knaflic, 2015-10-09 Don't simply show your data—tell a story with it! Storytelling with Data teaches you the fundamentals of data visualization and how to communicate effectively with data. You'll discover the power of storytelling and the way to make data a pivotal point in your story. The lessons in this illuminative text are grounded in theory, but made accessible through numerous real-world examples—ready for immediate application to your next graph or presentation. Storytelling is not an inherent skill, especially when it comes to data visualization, and the tools at our disposal don't make it any easier. This book demonstrates how to go beyond conventional tools to reach the root of your data, and how to use your data to create an engaging, informative, compelling story. Specifically, you'll learn how to: Understand the importance of context and audience Determine the appropriate type of graph for your situation Recognize and eliminate the clutter clouding your information Direct your audience's attention to the most important parts of your data Think like a designer and utilize concepts of design in data visualization Leverage the power of storytelling to help your message resonate with your audience Together, the lessons in this book will help you turn your data into high impact visual stories that stick with your audience. Rid your world of ineffective graphs, one exploding 3D pie chart at a time. There is a story in your data—Storytelling with Data will give you the skills and power to tell it! |
| data science in pharmaceutical industry: The Prevention and Treatment of Missing Data in Clinical Trials National Research Council, Division of Behavioral and Social Sciences and Education, Committee on National Statistics, Panel on Handling Missing Data in Clinical Trials, 2010-12-21 Randomized clinical trials are the primary tool for evaluating new medical interventions. Randomization provides for a fair comparison between treatment and control groups, balancing out, on average, distributions of known and unknown factors among the participants. Unfortunately, these studies often lack a substantial percentage of data. This missing data reduces the benefit provided by the randomization and introduces potential biases in the comparison of the treatment groups. Missing data can arise for a variety of reasons, including the inability or unwillingness of participants to meet appointments for evaluation. And in some studies, some or all of data collection ceases when participants discontinue study treatment. Existing guidelines for the design and conduct of clinical trials, and the analysis of the resulting data, provide only limited advice on how to handle missing data. Thus, approaches to the analysis of data with an appreciable amount of missing values tend to be ad hoc and variable. The Prevention and Treatment of Missing Data in Clinical Trials concludes that a more principled approach to design and analysis in the presence of missing data is both needed and possible. Such an approach needs to focus on two critical elements: (1) careful design and conduct to limit the amount and impact of missing data and (2) analysis that makes full use of information on all randomized participants and is based on careful attention to the assumptions about the nature of the missing data underlying estimates of treatment effects. In addition to the highest priority recommendations, the book offers more detailed recommendations on the conduct of clinical trials and techniques for analysis of trial data. |
Data and Digital Outputs Management Plan (DDOMP)
Data and Digital Outputs Management Plan (DDOMP)
Building New Tools for Data Sharing and Reuse through a …
Jan 10, 2019 · The SEI CRA will closely link research thinking and technological innovation toward accelerating the full path of discovery-driven data use and open science. This will …
Open Data Policy and Principles - Belmont Forum
The data policy includes the following principles: Data should be: Discoverable through catalogues and search engines; Accessible as open data by default, and made available with …
Belmont Forum Adopts Open Data Principles for Environmental …
Jan 27, 2016 · Adoption of the open data policy and principles is one of five recommendations in A Place to Stand: e-Infrastructures and Data Management for Global Change Research, …
Belmont Forum Data Accessibility Statement and Policy
The DAS encourages researchers to plan for the longevity, reusability, and stability of the data attached to their research publications and results. Access to data promotes reproducibility, …
Climate-Induced Migration in Africa and Beyond: Big Data and …
CLIMB will also leverage earth observation and social media data, and combine them with survey and official statistical data. This holistic approach will allow us to analyze migration process …
Advancing Resilience in Low Income Housing Using Climate …
Jun 4, 2020 · Environmental sustainability and public health considerations will be included. Machine Learning and Big Data Analytics will be used to identify optimal disaster resilient …
Belmont Forum
What is the Belmont Forum? The Belmont Forum is an international partnership that mobilizes funding of environmental change research and accelerates its delivery to remove critical …
Waterproofing Data: Engaging Stakeholders in Sustainable Flood …
Apr 26, 2018 · Waterproofing Data investigates the governance of water-related risks, with a focus on social and cultural aspects of data practices. Typically, data flows up from local levels …
Data Management Annex (Version 1.4) - Belmont Forum
A full Data Management Plan (DMP) for an awarded Belmont Forum CRA project is a living, actively updated document that describes the data management life cycle for the data to be …
Data and Digital Outputs Management Plan (DDOMP)
Data and Digital Outputs Management Plan (DDOMP)
Building New Tools for Data Sharing and Reuse through a …
Jan 10, 2019 · The SEI CRA will closely link research thinking and technological innovation toward accelerating the full path of discovery-driven data use and open science. This will …
Open Data Policy and Principles - Belmont Forum
The data policy includes the following principles: Data should be: Discoverable through catalogues and search engines; Accessible as open data by default, and made available with …
Belmont Forum Adopts Open Data Principles for Environmental …
Jan 27, 2016 · Adoption of the open data policy and principles is one of five recommendations in A Place to Stand: e-Infrastructures and Data Management for Global Change Research, …
Belmont Forum Data Accessibility Statement and Policy
The DAS encourages researchers to plan for the longevity, reusability, and stability of the data attached to their research publications and results. Access to data promotes reproducibility, …
Climate-Induced Migration in Africa and Beyond: Big Data and …
CLIMB will also leverage earth observation and social media data, and combine them with survey and official statistical data. This holistic approach will allow us to analyze migration process …
Advancing Resilience in Low Income Housing Using Climate …
Jun 4, 2020 · Environmental sustainability and public health considerations will be included. Machine Learning and Big Data Analytics will be used to identify optimal disaster resilient …
Belmont Forum
What is the Belmont Forum? The Belmont Forum is an international partnership that mobilizes funding of environmental change research and accelerates its delivery to remove critical …
Waterproofing Data: Engaging Stakeholders in Sustainable Flood …
Apr 26, 2018 · Waterproofing Data investigates the governance of water-related risks, with a focus on social and cultural aspects of data practices. Typically, data flows up from local levels …
Data Management Annex (Version 1.4) - Belmont Forum
A full Data Management Plan (DMP) for an awarded Belmont Forum CRA project is a living, actively updated document that describes the data management life cycle for the data to be …
